全文获取类型
收费全文 | 5658篇 |
免费 | 270篇 |
国内免费 | 46篇 |
专业分类
耳鼻咽喉 | 49篇 |
儿科学 | 114篇 |
妇产科学 | 60篇 |
基础医学 | 653篇 |
口腔科学 | 116篇 |
临床医学 | 323篇 |
内科学 | 1606篇 |
皮肤病学 | 60篇 |
神经病学 | 418篇 |
特种医学 | 312篇 |
外科学 | 878篇 |
综合类 | 25篇 |
预防医学 | 184篇 |
眼科学 | 110篇 |
药学 | 388篇 |
中国医学 | 15篇 |
肿瘤学 | 663篇 |
出版年
2023年 | 32篇 |
2022年 | 57篇 |
2021年 | 96篇 |
2020年 | 62篇 |
2019年 | 71篇 |
2018年 | 105篇 |
2017年 | 80篇 |
2016年 | 99篇 |
2015年 | 135篇 |
2014年 | 158篇 |
2013年 | 164篇 |
2012年 | 311篇 |
2011年 | 312篇 |
2010年 | 165篇 |
2009年 | 173篇 |
2008年 | 261篇 |
2007年 | 237篇 |
2006年 | 255篇 |
2005年 | 251篇 |
2004年 | 253篇 |
2003年 | 218篇 |
2002年 | 257篇 |
2001年 | 207篇 |
2000年 | 201篇 |
1999年 | 185篇 |
1998年 | 78篇 |
1997年 | 73篇 |
1996年 | 60篇 |
1995年 | 41篇 |
1994年 | 40篇 |
1993年 | 43篇 |
1992年 | 133篇 |
1991年 | 125篇 |
1990年 | 100篇 |
1989年 | 118篇 |
1988年 | 81篇 |
1987年 | 67篇 |
1986年 | 78篇 |
1985年 | 76篇 |
1984年 | 62篇 |
1983年 | 51篇 |
1982年 | 23篇 |
1980年 | 21篇 |
1979年 | 52篇 |
1978年 | 25篇 |
1977年 | 30篇 |
1976年 | 24篇 |
1974年 | 24篇 |
1971年 | 22篇 |
1969年 | 21篇 |
排序方式: 共有5974条查询结果,搜索用时 15 毫秒
101.
Hisao Higo Hirohisa Ichikawa Naoki Nakamura Masanori Fujii Katsuhiro Matsuoka Shoko Seki Takamasa Wada Noriyuki Suzaki Takuya Nagata Yukako Arakawa Yoshihiro Mori Masaomi Marukawa Katsuyuki Kiura Yoshinobu Maeda Nobuaki Miyahara 《Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG / World Association of Sarcoidosis and Other Granulomatous Disorders》2022,39(4)
Background and aim:Acute exacerbation (AE) of idiopathic pulmonary fibrosis (IPF) is a fatal condition with no established treatment. Intravenous immunoglobulin (IVIG) is a unique therapy with both anti-inflammatory and anti-infective effects. Therefore, we hypothesized that IVIG may have a positive effect on AE of interstitial pneumonia. This study aimed to determine the effect of IVIG in patients with AE of fibrotic idiopathic interstitial pneumonias (IIPs), including IPF.Methods:We retrospectively analyzed consecutive patients who were diagnosed with AE of fibrotic IIPs and treated with pulse corticosteroid therapy (methylprednisolone 500–1000 mg/day for 3 days) between April 2018 and May 2021 at Kagawa Rosai Hospital and KKR Takamatsu Hospital.Results:This study included 52 patients with AE of fibrotic IIPs (IPF,41; fibrotic IIPs other than IPF,11). Thirteen patients received IVIG (5 g/day for 3–5 days) concurrently with pulse corticosteroid therapy. The remaining 39 patients were assigned to the control group. The survival rate on day 90 was significantly higher in the IVIG group than that in the control group (76.9% vs. 38.5%, p = 0.02). IVIG administration (odds ratio [OR], 0.11; 95% confidence interval [CI], 0.02–0.69; p = 0.02) and C- reactive protein (OR, 1.19; 95% CI, 1.06–1.33, p < 0.01) were independently associated with 90-day mortality.Conclusions:The results indicate that administration of IVIG may improve the survival of patients with AE of fibrotic IIPs. We are now conducting a prospective study to confirm the effect of IVIG on AE of IPF since May 2022 (jRCT1061220010). 相似文献
102.
Taro Horino Tomohiro Eguchi Satoshi Inotani Akira Hirose Masayuki Ishihara Kenichi Yagyu Kazushige Uchida Mikiya Fujieda Yoshio Terada 《Internal medicine (Tokyo, Japan)》2023,62(1):91
Vascular endothelial growth factor inhibitors and checkpoint inhibitors are effective treatments for solid tumors. These new classes of anti-cancer agents frequently cause kidney-related side effects. Although their anti-cancer effects may be enhanced when used in combination, the severity of their kidney-related side effects is unknown. We herein report the first case of thrombotic microangiopathy and mesangial proliferative glomerulonephritis caused by combined treatment with atezolizumab and bevacizumab in a 74-year-old man with hepatocellular carcinoma. The combination therapy was discontinued and replaced with intravenous methylprednisolone followed by oral prednisolone. Subsequently, the urinary protein excretion levels declined. 相似文献
103.
Chiaki Imai Hiromi Saeki Kohei Yamamoto Ayano Ichikawa Makoto Arai Akinobu Tawada Takaaki Suzuki Yuichi Takiguchi Toyoyuki Hanazawa Itsuko Ishii 《Oncology Letters》2022,23(5)
Clinical trials have not fully demonstrated the efficacy and safety of radiotherapy plus cetuximab for locally advanced squamous cell head and neck cancer (LA-SCCHN) in patients with cisplatin-ineligible renal dysfunction. Patients who received radiotherapy plus cetuximab for LA-SCCHN at Chiba University Hospital (Chiba, Japan) between July 2013 and October 2018 were retrospectively reviewed. Background characteristics and locoregional control and overall survival rates were compared between patients with and without renal dysfunction. Survival was examined using Kaplan-Meier analysis and an adjusted Cox proportional hazards model. Kaplan-Meier analysis demonstrated that overall survival was shorter in patients with creatinine clearance of <45 ml/min (P=0.041; log-rank test). However, there was no difference in the locoregional control rate (P=0.477; log-rank test). Adjusted Cox analysis revealed that the risk of death was increased by 2.52-fold (hazard ratio, 2.52; 95% confidence interval, 1.01-6.30; P=0.048) if creatinine clearance was <45 ml/min. Moderate to severe renal dysfunction did not affect the locoregional control rate in patients with LA-SCCHN treated with radiotherapy plus cetuximab but was an adverse prognostic factor. 相似文献
104.
105.
106.
Aki Masuzawa Chikako Kiyotani Tomoo Osumi Yoko Shioda Kazutoshi Iijima Osamu Tomita Kazuhiko Nakabayashi Keisuke Oboki Kazuki Yasuda Hiromi Sakamoto Hitoshi Ichikawa Kenichiro Hata Teruhiko Yoshida Kenji Matsumoto Nobutaka Kiyokawa Tetsuya Mori 《European journal of haematology》2014,92(3):263-267
In addition to BCR, various rare fusion partners for the ABL1 gene have been reported in leukemia. We have identified the fusion gene SNX2‐ABL1 in a pediatric case of acute lymphoblastic leukemia (ALL), which has only once previously been reported in an adult patient. Cytogenetic analysis detected this fusion gene arising from a t(5;9)(q22;q34) translocation. ALL cells carrying a SNX2‐ABL1 fusion exhibited a BCR‐ABL1+ ALL‐like gene expression profile. The patient poorly responded to dasatinib but partially responded to imatinib. Treatment using tyrosine kinase inhibitors requires further investigation to optimize the genotype‐based treatment stratification for patients with SNX2‐ABL1 fusion. 相似文献
107.
Results of a 36‐year surveillance program for ulcerative colitis‐associated neoplasia in the Japanese population 下载免费PDF全文
Junko Kishikawa Keisuke Hata Shinsuke Kazama Hiroyuki Anzai Takahide Shinagawa Koji Murono Manabu Kaneko Kazuhito Sasaki Koji Yasuda Kensuke Otani Takeshi Nishikawa Toshiaki Tanaka Tomomichi Kiyomatsu Kazushige Kawai Hiroaki Nozawa Soichiro Ishihara Teppei Morikawa Masashi Fukayama Toshiaki Watanabe 《Digestive endoscopy》2018,30(2):236-244
108.
109.
Miyaaki H Ichikawa T Yatsuhashi H Taura N Miuma S Usui T Mori S Kamihira S Tanaka Y Mizokami M Nakao K 《Hepatology research》2011,41(12):1216-1222
Aim: The aim of this study was to investigate the relationship among the expression of suppressor of cytokine signaling 3 (SOCS 3) in the liver, the SNPs in the IL28B locus, and the outcome of interferon therapy. Methods: Prior to interferon treatment, we immunostained 67 liver specimens from chronic hepatitis C (CHC) patients who were receiving peginterferon alpha‐2b/ribavirin therapy for suppressor of cytokine signaling 3 (SOCS3), and compared the expression of SOCS3, IL28 polymorphisms and other clinical factors between the patients and compared their eventual outcomes. Results: Significant differences between the low SOCS3 group and high SOCS3 group were found in age, as well as in the platelet, transaminase, gamma‐glutamyl transpeptidase levels. The incidence of high SOCS3 was not significantly different between subjects with the TT genotype and the TG genotype (TT : TG = 71%:29%, P = 0.250). In a multivariate analysis, age (≥65 years old) (odds ratio 0.221 [0.120–0.966], P = 0.045), IL28B gene (genotype TT) (odds ratio 5.422 [1.254–23.617], P = 0.024) and SOCS3 (high) (odds ratio 0.308 [0.104–0.948], P = 0.040) were significant predictors of the interferon response. In patients with the TT genotype, those with low SOCS3 immunostaining showed a high sustained virological response (69%), while the sustained virological rate was low (27%) in the patients with high SOCS3 immunostaining. Conclusions: Using a combination of the SOCS3 immunostained area in the liver and the expression of IL28B single nucleotide polymorphisms might be a useful predictor of hepatitis C virus clearance by interferon therapy. 相似文献